IL244202D0 - Azaspiro[4.5] decane derivatives and use thereof - Google Patents

Azaspiro[4.5] decane derivatives and use thereof

Info

Publication number
IL244202D0
IL244202D0 IL244202A IL24420216A IL244202D0 IL 244202 D0 IL244202 D0 IL 244202D0 IL 244202 A IL244202 A IL 244202A IL 24420216 A IL24420216 A IL 24420216A IL 244202 D0 IL244202 D0 IL 244202D0
Authority
IL
Israel
Prior art keywords
azaspiro
decane derivatives
decane
derivatives
Prior art date
Application number
IL244202A
Other languages
Hebrew (he)
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201361869941P priority Critical
Priority to US201461987727P priority
Priority to PCT/US2014/050549 priority patent/WO2015031036A1/en
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of IL244202D0 publication Critical patent/IL244202D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
IL244202A 2013-08-26 2016-02-21 Azaspiro[4.5] decane derivatives and use thereof IL244202D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201361869941P true 2013-08-26 2013-08-26
US201461987727P true 2014-05-02 2014-05-02
PCT/US2014/050549 WO2015031036A1 (en) 2013-08-26 2014-08-11 Azaspiro[4.5] decane derivatives and use thereof

Publications (1)

Publication Number Publication Date
IL244202D0 true IL244202D0 (en) 2016-04-21

Family

ID=52587202

Family Applications (1)

Application Number Title Priority Date Filing Date
IL244202A IL244202D0 (en) 2013-08-26 2016-02-21 Azaspiro[4.5] decane derivatives and use thereof

Country Status (7)

Country Link
US (2) US9884865B2 (en)
EP (1) EP3039019B1 (en)
JP (2) JP6422498B2 (en)
CN (1) CN105612152A (en)
CA (1) CA2922567A1 (en)
IL (1) IL244202D0 (en)
WO (1) WO2015031036A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2593434A1 (en) 2010-07-16 2013-05-22 Purdue Pharma LP Pyridine compounds as sodium channel blockers
EP2616441B1 (en) 2010-09-17 2019-08-07 Purdue Pharma L.P. Pyridine compounds and the uses thereof
JP2013540130A (en) 2010-10-05 2013-10-31 パーデュー、ファーマ、リミテッド、パートナーシップ Quinazoline compounds as sodium channel blockers
EP2655330B1 (en) 2010-12-22 2016-02-10 Purdue Pharma LP Substituted pyridines as sodium channel blockers
EP2753606B1 (en) 2011-09-02 2017-07-05 Purdue Pharma LP Pyrimidines as sodium channel blockers
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
US9181185B2 (en) 2011-10-31 2015-11-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
US9206127B2 (en) 2012-03-16 2015-12-08 Purdue Pharm, L.P. Substituted pyridines as sodium channel blockers
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
JP6110516B2 (en) 2013-03-04 2017-04-05 パーデュー、ファーマ、リミテッド、パートナーシップ Pyrimidine carboxamides as sodium channel blockers
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
JP6186494B2 (en) 2013-03-15 2017-08-23 パーデュー、ファーマ、リミテッド、パートナーシップ Carboxamide derivatives and uses thereof
US9884865B2 (en) 2013-08-26 2018-02-06 Purdue Pharma L.P. Azaspiro[4.5] decane derivatives and use thereof
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
AU2014370407B2 (en) 2013-12-23 2018-03-29 Purdue Pharma L.P. Indazoles and use thereof
WO2015112801A1 (en) 2014-01-24 2015-07-30 Purdue Pharma L.P. Pyridines and pyrimidines and use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
GB201416352D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
GB201416351D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives
GB201522179D0 (en) * 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
KR20200038545A (en) 2017-08-04 2020-04-13 스카이호크 테라퓨틱스, 인코포레이티드 Methods and compositions for modulating splicing
CR20200347A (en) 2018-02-13 2020-09-23 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
EP3556760A1 (en) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN112399874A (en) 2018-07-13 2021-02-23 吉利德科学公司 PD-1/PD-L1 inhibitors

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010020201A (en) 1997-04-22 2001-03-15 코센시스 인크 Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
SK156499A3 (en) * 1997-05-30 2000-06-12 Upjohn Co Oxazolidinone antibacterial agents having a thiocarbonyl functionality
EP2201944B1 (en) 1997-11-21 2012-05-23 Purdue Neuroscience Company Use of substituted 2-aminoacetamides for treating, preventing or ameliorating manic depression
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
CN1353605A (en) 1999-03-26 2002-06-12 欧洲凯尔特股份有限公司 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and use thereof
JP2002541215A (en) 1999-04-09 2002-12-03 ユーロ−セルティック エス. ア. Sodium channel blocker compositions and uses thereof
AR029489A1 (en) 2000-03-10 2003-07-02 Euro Celtique Sa Pyridines, pyrimidines, pyrazines, aryl substituted triazines, pharmaceutical compositions and their use for the manufacture of a drug
AU4589701A (en) 2000-03-24 2001-10-08 Cocensys Inc Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof
CA2403991A1 (en) 2000-03-31 2001-10-11 Euro-Celtique S.A. Aminopyridines and their use as anticonvulsants and sodium channel blockers
US6600015B2 (en) * 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
EP1417187A1 (en) 2001-07-16 2004-05-12 Euro-Celtique S.A. Aryl substituted thiazolidinones and the use thereof
AR036873A1 (en) 2001-09-07 2004-10-13 Euro Celtique Sa Aryl substituted pyridines, pharmaceutical compositions and the use thereof for the preparation of a medicament
AR037233A1 (en) 2001-09-07 2004-11-03 Euro Celtique Sa Aryl substituted pyridines, pharmaceutical compositions and the use of said compounds for the manufacture of a medicine
WO2003076414A2 (en) 2002-03-13 2003-09-18 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof
KR20050026023A (en) 2002-07-31 2005-03-14 유로-셀티큐 에스.에이. Aryl substituted hydantoin compounds and their use as sodium channel blockers
CA2492305A1 (en) 2002-07-31 2004-02-05 Euro-Celtique S.A. Aryl substituted benzimidazoles and their use as sodium channel blockers
US20040152696A1 (en) 2002-08-01 2004-08-05 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers
WO2004050857A2 (en) 2002-12-04 2004-06-17 Euro-Celtique S.A. Splice variant of human sodium iii channel (hnaiii18)
WO2004111011A2 (en) 2003-05-30 2004-12-23 Euro-Celtique S.A. Synthesis of 2-aryl pyrimidine 4-carboxylic acid amides
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
CA2578168A1 (en) 2004-08-27 2006-03-02 Astellas Pharma Inc. 2-phenylpyridine derivative
WO2008153042A1 (en) * 2007-06-11 2008-12-18 Kyowa Hakko Kirin Co., Ltd. Anti-tumor agent
JP2012528872A (en) * 2009-06-03 2012-11-15 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
US9334269B2 (en) 2010-02-17 2016-05-10 Amgen Inc. Carboxamides as inhibitors of voltage-gated sodium channels
JP2013530180A (en) 2010-06-16 2013-07-25 パーデュー、ファーマ、リミテッド、パートナーシップ Aryl substituted indoles and uses thereof
EP2593434A1 (en) 2010-07-16 2013-05-22 Purdue Pharma LP Pyridine compounds as sodium channel blockers
EP2616441B1 (en) 2010-09-17 2019-08-07 Purdue Pharma L.P. Pyridine compounds and the uses thereof
JP2013540130A (en) 2010-10-05 2013-10-31 パーデュー、ファーマ、リミテッド、パートナーシップ Quinazoline compounds as sodium channel blockers
US9056865B2 (en) * 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2-derivatives as smoothened receptor modulators
EP2655330B1 (en) 2010-12-22 2016-02-10 Purdue Pharma LP Substituted pyridines as sodium channel blockers
AU2012227383B2 (en) * 2011-03-15 2016-05-19 Astellas Pharma Inc. Guanidine compound
EP2753606B1 (en) 2011-09-02 2017-07-05 Purdue Pharma LP Pyrimidines as sodium channel blockers
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
US9181185B2 (en) 2011-10-31 2015-11-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
US9206127B2 (en) 2012-03-16 2015-12-08 Purdue Pharm, L.P. Substituted pyridines as sodium channel blockers
US9718865B2 (en) 2012-07-27 2017-08-01 Purdue Pharma L.P. Sodium channel blocking peptides and the use thereof
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
JP6110516B2 (en) 2013-03-04 2017-04-05 パーデュー、ファーマ、リミテッド、パートナーシップ Pyrimidine carboxamides as sodium channel blockers
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
JP6186494B2 (en) 2013-03-15 2017-08-23 パーデュー、ファーマ、リミテッド、パートナーシップ Carboxamide derivatives and uses thereof
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
US9884865B2 (en) 2013-08-26 2018-02-06 Purdue Pharma L.P. Azaspiro[4.5] decane derivatives and use thereof
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
EP3083606B1 (en) 2013-12-20 2020-10-28 Purdue Pharma LP Pyrimidines and use thereof
AU2014370407B2 (en) 2013-12-23 2018-03-29 Purdue Pharma L.P. Indazoles and use thereof
US9862726B2 (en) 2013-12-26 2018-01-09 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
US9656962B2 (en) 2013-12-26 2017-05-23 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
WO2015112801A1 (en) 2014-01-24 2015-07-30 Purdue Pharma L.P. Pyridines and pyrimidines and use thereof
CA2939501C (en) 2014-02-12 2020-07-07 Purdue Pharma L.P. Isoquinoline derivatives and use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
CN107613965A (en) 2015-02-19 2018-01-19 普渡制药公司 For reducing the method and composition of gastric emptying

Also Published As

Publication number Publication date
JP2019031531A (en) 2019-02-28
US20180134707A1 (en) 2018-05-17
CN105612152A (en) 2016-05-25
EP3039019A4 (en) 2017-05-17
JP2016529294A (en) 2016-09-23
EP3039019B1 (en) 2020-04-22
US20160207923A1 (en) 2016-07-21
WO2015031036A1 (en) 2015-03-05
JP6422498B2 (en) 2018-11-14
CA2922567A1 (en) 2015-03-05
US9884865B2 (en) 2018-02-06
EP3039019A1 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
HRP20200846T1 (en) Anti-il-33 antibodies and uses thereof
HRP20181392T1 (en) Heterocyclic compounds and uses thereof
HRP20181742T1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
HK1223351A1 (en) Heterocyclic compounds and uses thereof
IL245643D0 (en) Mri-incubator's closure assembly
IL243974D0 (en) Anti-prlr antibodies and uses thereof
HK1220373A1 (en) Il-33 antagonists and uses thereof il-33
IL246221D0 (en) Indazoles and use thereof
ZA201602220B (en) Heterocyclic compounds and uses thereof
ZA201504537B (en) Anti-pdgfr-beta antibodies and uses thereof
EP3003087A4 (en) Integrated closure device components and methods
EP2991661A4 (en) Conjugated antisense compounds and their use
HK1215795A1 (en) Amatoxin derivatives
IL240517D0 (en) Anti-b7-h4 antibodies and immunoconjugates
HK1220626A1 (en) Cytotoxic and anti-mitotic compounds, and methods of using the same
IL240221D0 (en) Benzomorphan analogs and the use thereof
IL247252D0 (en) Isoquinoline derivatives and use thereof
IL274355A (en) Aza-pyridone compounds and uses thereof
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
AU2014329392A1 (en) Heterocyclic compounds and uses thereof
EP2967081A4 (en) Modified caspase polypeptides and uses thereof
EP2968304A4 (en) 4-phenylpiperidines, their preparation and use
PL2943483T3 (en) Benzylamine derivatives
EP3083448A4 (en) Capsule with sensory attributes
EP2968307A4 (en) Carboxamide derivatives and use thereof